Table 1.
Demographics and practice characteristics of clinician respondents.
| Demographics characteristics | n | % |
|---|---|---|
| Practice location | ||
| Academic Medical Center with patient care practice | 72 | 75.0 |
| Community Hospital based practice | 9 | 9.4 |
| Private patient care practice | 8 | 8.3 |
| Academic Medical Center without patient care practice | 3 | 3.1 |
| Other | 4 | 4.2 |
| Specialty | ||
| Gastroenterologist | 34 | 35.4 |
| Colorectal surgeon | 15 | 15.6 |
| Genetic Counselor in Cancer Genetics | 13 | 13.5 |
| Medical geneticist | 10 | 10.4 |
| Medical oncologist | 9 | 9.4 |
| Other | 15 | 15.6 |
| Geographic location | ||
| North America | 50 | 52.1 |
| USA | 45 | |
| Canada | 5 | |
| Australia/New Zealand | 4 | 4.2 |
| South America | 15 | 15.6 |
| Europe | 16 | 16.7 |
| Asia | 4 | 4.2 |
| United Kingdom | 7 | 7.3 |
| Practice characteristics | ||
| Years providing hereditary gastrointestinal cancer risk assessment | ||
| Less than 5 years | 12 | 13.8 |
| 5-10 years | 19 | 21.8 |
| 10 years or more | 56 | 64.4 |
| Number of LS and FAP patients seen per week | ||
| Less than 5 | 48 | 55.2 |
| 5-10 | 27 | 31.0 |
| More than 10 | 10 | 11.5 |
| NA | 2 | 2.3 |
| Offer chemoprevention for LS and/or FAP patients as a part of their practice | ||
| Yes | 60 | 69.0 |
| No | 20 | 23.0 |
| Other | 7 | 8.0 |
| Years that their hospital/service started prescribing chemoprevention | ||
| 1989-2009 | 3 | 6.0 |
| 2010-2021 | 28 | 56.0 |
| Uncertain | 19 | 38.0 |